Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2017

01-11-2017 | Original Article

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

Authors: Zahra Malek-Hosseini, Sina Jelodar, Abdolrasoul Talei, Abbas Ghaderi, Mehrnoosh Doroudchi

Published in: Breast Cancer | Issue 6/2017

Login to get access

Abstract

Background

Breast cancer is the leading type of cancer in Iranian women and affects them at least one decade younger than their counterparts in developed countries. Breast tumor progression and metastasis is accompanied by a decrease in the membranous expression of Syndecan-1 and an increase in its shedding. We measured the level of soluble Syndecan-1 in the sera of Iranian patients with breast cancer.

Methods

The study population included 61 chemotherapy-naïve breast cancer patients and 30 age/sex-matched healthy individuals. Blood was collected by venipuncture method and serum was separated, aliquoted and kept at −40 °C until used. A commercial ELISA was used to detect Syndecan-1 levels in the sera.

Results

Soluble Syndecan-1 levels were increased in the sera of patients with breast cancer compared to healthy controls (87.89 ± 89.29 vs. 47.57 ± 46.46 ng/ml, p = 0.005). There was a positive correlation between soluble Syndecan-1 levels and tumor size (p = 0.017). The serum level of Syndecan-1 in patients without calcification showed a trend of increase compared to that of patients with calcification (108.80 ± 101.76 vs. 59.82 ± 57.13 ng/ml).

Conclusion

The positive correlation between soluble Syndecan-1 levels and tumor size in the present study highlights the importance of different varieties (cell-bound and soluble) of this molecule in the breast tumor progression and their significance as tumor biomarkers.
Appendix
Available only for authorised users
Literature
1.
Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma–rare types: review of the literature. Ann Oncol. 2009;20(11):1763–70.CrossRefPubMed
2.
WHO. Breast cancer: prevention and control. In: Organization WH, editor.
3.
Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.CrossRefPubMed
4.
Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519–27.CrossRefPubMed
5.
Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–7.PubMed
6.
Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. Iran Red Crescent Med J. 2012;14(12):798–804.CrossRefPubMedPubMedCentral
7.
Rahimzadeh M, Pourhoseingholi MA, Kavehie B. Survival rates for breast cancer in iranian patients: a meta-analysis. Asian Pac J Cancer Prev. 2016;17(4):2223–7.CrossRefPubMed
8.
Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11(6):541–52.CrossRefPubMed
9.
10.
Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells. 2007;24(2):153–66.PubMed
11.
Gotte M, Echtermeyer F. Syndecan-1 as a regulator of chemokine function. Sci World J. 2003;3:1327–31.CrossRef
12.
Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, et al. Role of the heparan sulfate proteoglycan Syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol (Baltimore, Md: 1950). 2009;182(8):4985–93.
13.
Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood. 2009;114(14):3033–43.CrossRefPubMedPubMedCentral
14.
Fears CY, Woods A. The role of syndecans in disease and wound healing. Matrix Biol. 2006;25(7):443–56.CrossRefPubMed
15.
Akl MR, Nagpal P, Ayoub NM, Prabhu SA, Gliksman M, Tai B, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget. 2015;6(30):28693–715.CrossRefPubMedPubMedCentral
16.
Shegefti MS, Malekzadeh M, Malek-Hosseini Z, Khademi B, Ghaderi A, Doroudchi M. Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma. Laryngoscope. 2016;126(5):E191–5.CrossRefPubMed
17.
Rintala M, Inki P, Klemi P, Jalkanen M, Grenman S. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol. 1999;75(3):372–8.CrossRefPubMed
18.
Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Can Res. 2001;61(14):5562–9.
19.
Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88(1):12–20.CrossRefPubMed
20.
Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble Syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30(3):397–407.CrossRefPubMed
21.
Szatmari T, Otvos R, Hjerpe A, Dolora K. Syndecan-1 in cancer: implications for cell signaling, differentiation, and prognostication. Dis Mark. 2015;2015:796052. doi:10.​1155/​2015/​796052.
22.
Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3–16.CrossRefPubMed
23.
Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST, Kim JG, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci. 2015;12(2):92–9.CrossRefPubMedPubMedCentral
24.
Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell. 1995;6(5):559–76.CrossRefPubMedPubMedCentral
25.
Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, et al. Shift of Syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer. 2004;40(9):1373–82.CrossRefPubMed
26.
Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of Syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713–20.CrossRefPubMed
27.
Ishikawa T, Kramer RH. Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res. 2010;316(6):951–65.CrossRefPubMed
28.
Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of Syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003;278(42):40764–70.CrossRefPubMed
29.
Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, et al. High Syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98(3):474–83.CrossRefPubMed
30.
Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of Syndecan-1 expression in breast cancer. Oncology. 2004;67(1):11–8.CrossRefPubMed
31.
Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, et al. Prognostic impact of Syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008;98(12):1993–8.CrossRefPubMedPubMedCentral
32.
Sanaee MN, Malekzadeh M, Khezri A, Ghaderi A, Doroudchi M. Soluble CD138/Syndecan-1 increases in the sera of patients with moderately differentiated bladder cancer. Urol Int. 2015;94(4):472–8.CrossRefPubMed
33.
34.
Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (Georgetown, Tex). 2012;11(15):2922–30.
35.
Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–84.CrossRefPubMedPubMedCentral
36.
Stiehl DP, Bordoli MR, Abreu-Rodriguez I, Wollenick K, Schraml P, Gradin K, et al. Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene. 2012;31(18):2283–97.CrossRefPubMed
37.
Ansell A, Jedlinski A, Johansson AC, Roberg K. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. J Oral Pathol Med. 2016;45(1):9–16.CrossRefPubMed
38.
Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122(1):1–8.CrossRefPubMed
39.
Ling H, Liu ZB, Xu LH, Xu XL, Liu GY, Shao ZM. Malignant calcification is an important unfavorable prognostic factor in primary invasive breast cancer. Asia Pac J Clin Oncol. 2013;9(2):139–45.CrossRefPubMed
40.
Nyante SJ, Lee SS, Benefield TS, Hoots TN, Henderson LM. The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer. 2016;. doi:10.​1002/​cncr.​30281.PubMed
Metadata
Title
Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size
Authors
Zahra Malek-Hosseini
Sina Jelodar
Abdolrasoul Talei
Abbas Ghaderi
Mehrnoosh Doroudchi
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0773-0

Other articles of this Issue 6/2017

Breast Cancer 6/2017 Go to the issue

Letter to the Editor

Questions about lower inner zone tumors in early-stage breast cancer

Letter to the Editor

Pure invasive lobular carcinoma versus mixed invasive lobular cancer and invasive ductal carcinoma: metastatic patterns differ?

Original Article

Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity

Original Article

The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients

Original Article

Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer

Original Article

High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits